SRR1516039
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.490
- KRAS_SIGNALING_DN+0.340
- SPERMATOGENESIS+0.330
- KRAS_SIGNALING_UP+0.250
- COAGULATION+0.210
- G2M_CHECKPOINT+0.120
- BILE_ACID_METABOLISM+0.090
- APICAL_SURFACE+0.080
- ALLOGRAFT_REJECTION+0.070
- INFLAMMATORY_RESPONSE+0.070
Top 10 suppressed
- DNA_REPAIR-0.480
- MYC_TARGETS_V2-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.460
- OXIDATIVE_PHOSPHORYLATION-0.440
- TGF_BETA_SIGNALING-0.430
- PROTEIN_SECRETION-0.420
- ADIPOGENESIS-0.350
- MYC_TARGETS_V1-0.350
- PI3K_AKT_MTOR_SIGNALING-0.350
- INTERFERON_ALPHA_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG835 | — | — | 0.906 |
| 2 | MNG1123 | — | — | 0.880 |
| 3 | SRR1360150 | GTEX | — | 0.873 |
| 4 | MNG1143 | — | — | 0.864 |
| 5 | GSM5359442 | — | — | 0.861 |
| 6 | SRR1408113 | GTEX | — | 0.859 |
| 7 | MNG874 | — | — | 0.855 |
| 8 | SRR12202490 | — | — | 0.854 |
| 9 | MNG1139 | — | — | 0.852 |
| 10 | MDT-AP-2051 | Med | Medulloblastoma | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.490 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| COMPLEMENT | 0.040 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |